BCLI Brainstorm Cell Therapeutics Inc
Price (delayed)
$0.876
Market cap
$5.71M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.31
Enterprise value
$6.55M
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of
Highlights
The EPS has surged by 62% year-on-year and by 34% since the previous quarter
The net income has increased by 32% YoY and by 18% QoQ
BCLI's debt is up by 21% from the previous quarter but it is down by 20% YoY
BCLI's quick ratio has shrunk by 82% YoY
The equity has plunged by 60% YoY and by 28% from the previous quarter
Key stats
What are the main financial stats of BCLI
Market
Valuations
Earnings
Shares outstanding
6.52M
Market cap
$5.71M
Enterprise value
$6.55M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$11.69M
Net income
-$11.62M
EBIT
-$11.55M
EBITDA
-$11.31M
Free cash flow
-$9.08M
Per share
Balance sheet
Liquidity
EPS
-$2.31
EPS diluted
-$2.31
Free cash flow per share
-$1.81
Book value per share
-$1.36
Revenue per share
$0
TBVPS
$0.36
Total assets
$1.83M
Total liabilities
$9.6M
Debt
$1.02M
Equity
-$7.76M
Working capital
-$8.59M
Debt to equity
-0.13
Current ratio
0.04
Quick ratio
0.03
Net debt/EBITDA
-0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-360.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCLI stock price
How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
10.19%
1 week
-4.11%
1 month
-44.56%
1 year
-89.2%
YTD
-61.41%
QTD
-30.48%
Financial performance
How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.69M
Net income
-$11.62M
Gross margin
N/A
Net margin
N/A
Brainstorm Cell Therapeutics's operating income has increased by 45% YoY and by 12% QoQ
The net income has increased by 32% YoY and by 18% QoQ
Growth
What is Brainstorm Cell Therapeutics's growth rate over time
Valuation
What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 62% year-on-year and by 34% since the previous quarter
The equity has plunged by 60% YoY and by 28% from the previous quarter
Efficiency
How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has declined by 23% year-on-year but it has increased by 3.3% since the previous quarter
Dividends
What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCLI.
Financial health
How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total assets is 81% less than its total liabilities
Brainstorm Cell Therapeutics's current ratio has shrunk by 83% YoY and by 20% QoQ
BCLI's quick ratio has shrunk by 82% YoY
BCLI's debt is 113% more than its equity
The equity has plunged by 60% YoY and by 28% from the previous quarter
The company's debt to equity has surged by 50% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.